|Day's range||2.2200 - 2.2200|
The FDA grants priority review to Vertex (VRTX)/CRISPR's (CRSP) filings for exa-cel in SCD, with a final decision expected in December.
BOSTON, June 09, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that 12 scientific abstracts on the company’s portfolio of cystic fibrosis (CF) medicines were presented at this year’s European Cystic Fibrosis Society's (ECFS) 46th European Cystic Fibrosis Conference held June 7-10, 2023, in Vienna, Austria. Together, the data presented show the long-term benefits of treatment with CFTR modulators as well as the importance of treating the underlying cause of CF as early
Biotech stocks have taken investors on an unpredictable ride so far in 2023. Two of the better biotech stocks I see this month are Gilead Sciences (NASDAQ: GILD) and Vertex Pharmaceuticals (NASDAQ: VRTX). While Gilead's shares are down more than 11% so far this year, Vertex's shares are up more than 14%.
Vertex Pharmaceuticals' (NASDAQ:VRTX) stock is up by a considerable 16% over the past three months. Given that the...
BOSTON & ZUG, Switzerland, June 09, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that both pivotal trials for exagamglogene autotemcel (exa-cel) in patients with transfusion-dependent beta thalassemia (TDT) or severe sickle cell disease (SCD) met primary and key secondary endpoints at pre-specified interim analyses. The results are being presented at the Annual European Hematology Association (EHA) Congress.
BOSTON & ZUG, Switzerland, June 08, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Applications (BLAs) for the investigational treatment exagamglogene autotemcel (exa-cel) for severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). The FDA has granted Priority Review for SCD and Standard Review for TDT and assigned Prescri
It's OK to be more cautious at times and more aggressive at others, but buying stocks regularly helps correct for natural market volatility. With that in mind, PayPal Holdings (NASDAQ: PYPL), Target (NYSE: TGT), Vertex Pharmaceuticals (NASDAQ: VRTX), Walt Disney (NYSE: DIS), and Chevron (NYSE: CVX) are worth buying in June. Trevor Jennewine (PayPal Holdings): It's no secret that digital payments are becoming more prevalent, but investors may not realize that digital wallets are driving that trend.
Most smaller biotech companies would love to follow in the footsteps of Vertex Pharmaceuticals (NASDAQ: VRTX). Let's turn to a smaller biotech that Vertex knows very well: CRISPR Therapeutics (NASDAQ: CRSP). The two companies are partners in a blood disorders program and recently submitted their treatment candidate for regulatory approval.
Vertex Pharmaceuticals (VRTX) stock is likely to be driven by several catalysts this year. Multiple clinical milestones are likely to be achieved in 2023 and 2024, both in its CF and non-CF portfolio.
These stocks are already performing well but could kick into higher gear in a new S&P 500 bull market.
Key Insights Vertex Pharmaceuticals' estimated fair value is US$431 based on 2 Stage Free Cash Flow to Equity Current...
A struggling economy and a bear market haven't been able to stop Vertex Pharmaceuticals (NASDAQ: VRTX). Vertex's forward multiple comes in at more than four times the upper bounds of this range. Also, the company's forward price-to earnings (P/E) multiple is higher than that of the biotech industry, which is currently about 15.
Let's consider three stocks that could: Vertex Pharmaceuticals (NASDAQ: VRTX), DexCom (NASDAQ: DXCM), and Amazon (NASDAQ: AMZN). Vertex Pharmaceuticals is doing great things. One of the drugmakers that was closest to entering this market with competing products recently threw in the towel.
These businesses have considerable growth runways ahead.
CRISPR Therapeutics (NASDAQ: CRSP) has been making headlines lately as a result of its groundbreaking gene-editing collaboration with Vertex Pharmaceuticals (NASDAQ: VRTX). The backstory is that the two companies recently filed for a spate of regulatory approvals for the CRISPR/Cas9 gene-edited product, exa-cel, as a functional cure for two rare blood disorders, sickle cell disease and transfusion-dependent beta thalassemia. What arguably hasn't been appreciated, however, is CRISPR's other clinical assets in immuno-oncology, regenerative medicine, and in vivo therapeutics.
BOSTON, May 30, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in the Goldman Sachs 44th Annual Global Healthcare Conference. Dr. Reshma Kewalramani, Chief Executive Officer and President, and Stuart A. Arbuckle, Executive Vice President and Chief Operating Officer, will participate in a fireside chat on Tuesday, June 13, 2023 at 2:40 p.m. PT.
Wall Street thinks this stock will rise 12% over the next 12 months. Let's first address why some on Wall Street don't have greater expectations for Vertex. One of the biggest factors is the biotech stock's previous success.
The good news is that if you've got the money and the time, it's not all that hard to find great investment options. If the company hits the high end of that range and its share price grows to reflect that internal growth, an initial investment of $10,000 would increase in value to over $163,000 in two decades. The company's infrastructure assets include natural gas pipelines, electricity transmission lines, smart meters, rail operations, toll roads, telecom towers, data centers, and semiconductor manufacturing foundries.
Here's why they chose CRISPR Therapeutics (NASDAQ: CRSP), Novocure (NASDAQ: NVCR), and Pfizer (NYSE: PFE). David Jagielski (CRISPR Therapeutics): Shares of CRISPR Therapeutics are trading below $70, but it may not be long before they take off. The company has a promising gene-editing therapy in exa-cel for rare blood disorders beta-thalassemia and sickle cell disease that it has been working on with Vertex Pharmaceuticals.
Warren Buffett thinks that near-term economic and market forecasts are "worse than useless." My hunch is that the U.S. economy is headed for a mild recession. Like most investors who aren't billionaires with the surname Buffett, I don't like to see the stocks I buy go down.
A few successful drugs are all that are required for a biotech company to shine. Vertex Pharmaceuticals (NASDAQ: VRTX) is well-known for its star product, Trikafta, a cystic fibrosis (CF) medicine. In the most recent first quarter, Trikafta contributed nearly $2.1 billion of the $2.3 billion in total product revenue.
Gene-editing healthcare therapies and renewable energy are two of the strongest trends today and for the next few years. Both sectors are worthy of sizable investments, particularly if you're looking to make long-term investments. CRISPR (clustered regularly interspaced short palindromic repeats) gene editing was discovered in 2012, and has the potential to revolutionize some aspects of health care.
CRISPR Therapeutics (NASDAQ: CRSP) and Teladoc Health (NYSE: TDOC) both score a win when it comes to innovation in healthcare. CRISPR has developed a gene-editing approach that aims to fix faulty genes responsible for disease. Teladoc leads in telemedicine, allowing patients to visit doctors from the comfort of an armchair at home.
Long-term investors recognize the benefits of a buy-and-hold strategy. The key to earning good returns is to buy good growth stocks and hold them while ignoring short-term headwinds. While 2022 was hard on most stocks, this year seems to be going pretty well for these two growth stocks.
Shares of Facebook's and Instagram's parent company, Meta Platforms (NASDAQ: META), tanked last year in response to top-line revenue that contracted for the first time since the company went public in 2012. In the fourth quarter of 2022, the company's operating margin shrank to 20%, which did not compare well to the 40% operating margin the company reported in 2021. To right the ship, Meta CEO Mark Zuckerberg announced sweeping layoffs earlier this year and declared 2023 would be a much-needed year of efficiency.